trig gered by her par ents' di vorce. She has, how ever, been hap pily mar ried for 1 year and has a sup por tive hus band. The pa tient was started on fluvox am ine that was in creased gradu ally to 250 mg daily, and at the same time, par oxet ine was gradu ally dis con tin ued. Af ter 6 weeks on fluvox am ine, she pre sented with wors en ing symp toms: she had be gun pull ing on her scalp hair as well as her eye lashes, and she had more bu limic symp toms, as well as an an gry, frustrated mood and sui ci dal idea tion. At this point, the pa tient agreed to the admini stra tion of a small dose of risperidone, 0.5 mg in the morn ing and 1 mg at night, to aug ment the fluvox am ine 250 mg daily. Sur pris ingly, in 1 week her symp toms started to fade, and the compul sive hair-pulling and bu limic symptoms were brought un der con trol. Over the fol low ing 6 to 8 months, her eyelashes grew to nor mal length, and she returned to her regu lar oc cu pa tion. Be cause the pa tient de cided to get pregnant, she pre ferred to dis con tinue her medi ca tion gradu ally, hav ing un derstood the risks in volved. In ter est ingly, 4 weeks later, as the risperi done was discon tin ued and the fluvox am ine was reduced, her com pul sive hair-pulling and bu limic symp toms started to re-emerge. Fur ther con trolled stud ies may be nec essary to ex am ine whether these novel antipsy chot ics per se can in duce OCD symp toms or whether the OCD symptoms elic ited are phe nome nol ogi cally re lated to the psy cho sis spec trum.
Are Newer Antidepressants Really "Better Tolerated"?

Dear Edi tor:
Newer an ti de pres sant agents (fluoxetine, ser tra line, par oxet ine, fluvox am ine, cita lo pram, ven la fax ine, ne fa zo done, mir tazepine, and bupropion) are con sidered to be bet ter tol er ated than are the older tri cyc lic an ti de pres sants (TCAs) and monoamine oxi dase in hibi tors (MAOIs) . But are they? The newer an tide pres sant medi ca tions also have signifi cant side ef fects. Side ef fects from se ro to ner gic agents may re sult from stimu la tion of 5-HT 2A (in som nia, anxiety or agi ta tion, and sex ual dys func tion), 5-HT 2C (ir ri ta bil ity and de creased ap petite), and 5-HT 3 (nau sea, vom it ing, and head ache). Side ef fects from newer agents may also re sult from nora dren ergic re cep tor stimu la tion (tachy car dia, blood pres sure ef fects, dry mouth, and sweat ing) as well as from in ter ac tions at other re cep tors in clud ing mus car inic, his ta min er gic, and post synap tic α 1 -adre ne rgic (dry mouth, se da tion, and postural hy poten sion) (1) . Treat ment in tol er ance is a fre quent cause of treatment fail ure or dis con tinua tion. I re port a case il lus trat ing a vast ar ray of sig nificant treat ment in tol er ance that has impacted on treat ment suc cess.
Ms A is a 36-year-old woman who was di ag nosed with ma jor de pres sion with on set around the fourth post par tum month. She opted to wait to com mence psy cho phar ma cologic treat ment un til she com pleted breast feed ing, which occurred around the eighth post par tum month. She was started on cita lo pram 20 mg daily and had a par tial clini cal response by the eighth week of treat ment. To ob tain com plete reso lu tion of symptoms, her dose was in creased to 40 mg daily, and she re ported sig nifi cant improve ment by the tenth week of treatment. At both 20 mg and 40 mg, Ms A re ported both er some sex ual dys func tion side ef fects. At 40 mg, she be gan to display new on set of easy bruis ing. In an attempt to treat the sex ual dys func tion, Ms A was given bupropion slow re lease (SR) 100 mg daily, with out any change in her sex ual func tion ing. Given the contin ued sex ual dys func tion and easy bruis ing, it was de cided to switch medica tions. Over the course of 3 days, citalo pram and bupropion SR were dis con tin ued, and she was started on ven la fax ine 37.5 mg twice daily. Dur ing the switch, Ms A com plained of symptoms con sis tent with an ti de pres sant discon tinua tion syn drome (anxi ety, agi ta tion, in som nia, light-headedness, diz zi ness, nau sea, and de pres sive symptoms). Over the course of 2 weeks, the ven la fax ine dose was in creased to 75 mg twice daily. Her sex ual dys func tion persisted, but her symp toms of easy bruising ceased when the cita lo pram was dis con tin ued. On ven la fax ine, Ms A com plained of sig nifi cant sleep in terrup tions and vivid dream ing that impaired daily func tion ing. Ven la fax ine was dis con tin ued with out symp toms of a dis con tinua tion syn drome, and Ms A was switched to ne fa zo done. She gradually ti trated her dose to 200 mg twice daily by the tenth day. On ne fa zo done, Ms A no longer com plained of sex ual dys func tion, bruis ing, or in som nia. She now, how ever, ex pe ri enced or thostatic hy poten sion, diz zi ness, and fa tigue Her blood pres sure was of par ticu lar con cern be cause it had been meas ured re peat edly at 80/50 mmHg (su pine and stand ing), and she had ex pe ri enced epi sodes in which she al most fainted dur ing pos tural changes. Al though she has ob tained a par tial re sponse with the ne fa zo done, the side ef fects have once again prompted Ms A to dis con tinue medi cation. She now re mains off psy cho pharma col ogy and is pur su ing psy cho ther apy.
This case high lights the cur rent problems that can be as so ci ated with the newer an ti de pres sants. For Ms A, problem atic side ef fects in cluded sex ual dysfunc tion, easy bruis ing, in som nia with sleep in ter rup tions and vivid dream ing, or thostatic hy poten sion, and fa tigue, as well as an ti de pres sant dis con tinua tion syn drome ex pe ri enced when switch ing medi ca tions. In tol er ance of newer an ti de pres sant agents con tin ues to be a sig nifi cant cause of treat ment fail ure, de spite the com mon be lief that these medi ca tions are "bet ter tol er ated" (2) (3) (4) .
Gabapentin Use in Benzodiazepine Dependence and Detoxification
Dear Edi tor:
Once pa tients be come de pend ent on ben zo di azepines, dis con tinu ing them of ten proves vex ing. De toxi fi ca tion ends up be ing pro longed or un suc cess ful due to with drawal or re-emergent anxiety (1), as well as to the need for an ex ternal source of con trol (2) . Ga bap en tin is a novel an ti con vul sant, struc tur ally analogous to gamma-aminobutyric acid (GABA), that pro motes GABA re lease via un known mecha nisms (3) . It has been re ported help ful in the man agement of pain syn dromes (4), anxi ety (5) (6) (7) , and al co hol with drawal (8) . We pres ent a case wherein de toxi fi ca tion from ben zo di azepines was aided by the use of ga bap en tin; there have been no pre vi ous simi lar re ports.
Mrs A was a 49-year-old woman with a 7-year his tory of con tinu ous de pendence on 12 to15 mg of al pra zo lam daily. Tol er ance, with drawal, and loss of control char ac ter ized her use, with marked in ter fer ence in her work and home life. Her ben zo di azepine de pend ence was com pli cated by Fiorinal-C½ and diphen hy dramine abuse. Com pound ing mat ters was a his tory of re cur rent panic and gen er al ized anxi ety, fre quent depres sive epi sodes with sui ci dal ity, and so ma ti za tion. She en tered hos pi tal af ter a sui cide at tempt in which she took 60 to 75 mg of al pra zo lam. De spite mul ti ple so matic com plaints, her physi cal status was un re mark able, with nor mal re nal func tion.
She was con tin ued on her pre vi ous paroxet ine at 20 mg daily. Al pra zo lam, barbi tu rates, opi ates, and an ti his ta mines were stopped. A clo naze pam ta per was started at 2 mg twice daily, with dose as needed for break through with drawal or marked anxi ety. On 1 mg of clo naze pam daily her ta per stalled; over whelm ing anxi ety, tremor, and af fec tive in sta bil ity pre vented fur ther dose re duc tion. Due to her in sta bil ity and con tin ued ben zo diazepine use, she was de clined en try into resi den tial ad dic tion treat ment. She refused car be mazepine be cause of po tential side ef fects. She in stead started on 200 mg of ga bap en tin 3 times daily. Initially as her symp toms of anxi ety, tremor, and af fec tive la bil ity rap idly decreased, she de scribed ga bap en tin as "feel ing like al pra zo lam." Clo naze pam was then ta pered off. Within 3 weeks of ad mis sion, she was benzodiazepinefree. The sub jec tive, alprazolam-like effect faded, but anx ious symp toms remained con trolled, with lit tle crav ing for ben zo di azepines or other sub stances, includ ing ciga rettes. She de nied any adverse ef fects from the medi ca tion, ex cept for short-term se da tion. The to tal daily dose of ga bap en tin re mained low (600 mg daily). Off ben zo di azepines, her men tal state im proved, al low ing discharge from hos pi tal and com mencement of out pa tient ad dic tion treat ment. Two months later, she re mained ab sti nent.
Car be mazepine has been used in ben zodi azepine de toxi fi ca tion (1), but its poten tial for ad verse ef fects ne ces si tates close moni tor ing and labo ra tory test ing. These con cerns pre cluded its use in this case. Al ter na tively, pro longed ben zo diazepine ta pers of ten fail (1, 9) or can obstruct en try into ad dic tion treat ment. In this case, the ad di tion of ga bap en tin appeared to ease the ben zo di azepine detoxi fi ca tion pro cess ap pre cia bly, short en ing over all with drawal time while side step ping com monly en countered prob lems. Ga bap en tin has a relatively be nign side-effect pro file with few known drug in ter ac tions, a wide thera peu tic win dow, does not re quire blood moni tor ing, and is not me tabolized by the liver (3, 4) . Its use may thus of fer a rea son able al ter na tive, be yond the cur rently avail able op tions, for withdraw ing benzodiazepine-dependent pa tients.
